Should I Buy RPTX? RPTX 2026 Analysis

Should You Buy Repare Therapeutics Inc (RPTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1 Day change

0.75%

52 Week Range

2.660

Analysis Updated At

2026/01/30

Not a good buy right now. The stock is trading around $2.65 despite an agreed acquisition value cited at ~$1.82/share, which implies unfavorable risk/reward for an impatient buyer: upside is capped unless a higher bid emerges, while deal-close at the stated terms would imply meaningful downside from current levels. With no proprietary buy signals today and technicals showing overbought conditions near resistance, this is an avoid/sell setup rather than a fresh entry.

Technical Analysis

Trend is bullish on moving averages (SMA_5 > SMA_20 > SMA_200), but momentum is stretched: RSI_6 ~83 (overbought). MACD histogram (-0.0106) remains below zero but is negatively contracting, suggesting downside momentum is waning, not that a new strong leg up is starting. Price is pressing resistance: Pivot 2.583, R1 2.64 (already at/through), R2 2.676; nearby supports are S1 2.526 and S2 2.49. Given overbought RSI right into R2, the near-term setup favors mean reversion/pullback rather than a clean breakout. Intellectia Proprietary Trading Signals: - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning is extremely call-heavy (OI put/call ~0.01; volume put/call ~0.0), indicating very bullish/one-sided sentiment or positioning consistent with event-driven speculation. Call OI is large (17,739) versus puts (116). Volume is elevated versus the 30-day average (today vs avg ~143%), suggesting heightened attention. IV stats show 30D IV ~55.68 with very low IV percentile/rank (0.8 / 0.21), implying implied volatility is low versus its own history despite a corporate event backdrop—often a sign the market is not pricing a large additional move beyond expectations, which reduces the attractiveness of chasing upside here.

Technical Summary

Sell

Buy

Positive Catalysts

- Any improved acquisition terms (raised bid) or a competing offer could re-rate the stock upward from the current level.
- Call-heavy options flow and elevated volume suggest some traders are positioned for upside outcomes.
- Short-term pattern stats provided indicate modest positive drift probabilities (next day/week/month).

Neutral/Negative Catalysts

is well above the referenced acquisition value (~$1.82/share), creating asymmetric downside if the transaction proceeds on those terms.
near resistance (R2 ~2.676), increasing near-term pullback risk.

Financial Performance

Latest quarter: 2025/Q3. Revenue increased to $11.62M (flat YoY at ~0.00% change). Profitability weakened materially: Net income fell to $3.258M (-109.47% YoY) and EPS to $0.08 (-109.88% YoY). Gross margin reported at 100 (flat). Overall, the quarter shows no clear accelerating growth trend and worsening earnings versus last year, which does not provide a fundamental tailwind to justify a price meaningfully above the stated acquisition value.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: TD Cowen (Marc Frahm) downgraded RPTX to Hold from Buy (2025-11-17) after the company agreed to be acquired (cited value ~$1.82/share), noting little risk to closing—i.e., limited incremental upside from here. Wall Street pros/cons view (based on provided data): Pros—deal visibility (expected close) and event-driven optionality if terms improve. Cons—upside appears capped under current terms, and at today’s price the skew is negative if the deal closes as described. Other flows: Hedge funds neutral (no significant trends last quarter), insiders neutral (no significant trends last month). Politician/congress activity: no recent congress trading data available in the last 90 days.

2 Analyst Rating

Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3 USD with a low forecast of 3 USD and a high forecast of 3 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 2.650

Low

Averages

High

Current: 2.650

Low

Averages

High

TD Cowen

Marc Frahm

Buy

Hold

downgrade

$1.82

AI Analysis

2025-11-17

Reason

TD Cowen

Marc Frahm

Price Target

$1.82

AI Analysis

2025-11-17

downgrade

Buy

Hold

Reason

TD Cowen analyst Marc Frahm downgraded Repare Therapeutics to Hold from Buy after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.

H.C. Wainwright

Buy

downgrade

$5 -> $3

2025-10-27

Reason

H.C. Wainwright

Price Target

$5 -> $3

2025-10-27

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Repare Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data "raises questions over its viability." As such, the firm removed risk-adjusted revenue forecasts for the agent.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RPTX

Unlock Now

RPTX Should I Buy

RPTX Should I Buy

Should You Buy Repare Therapeutics Inc (RPTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch